The therapeutic market of Hidradenitis Suppurativa in the 7MM was USD 718.3 Million in 2017.
In 2017, the total prevalent population of Hidradenitis Suppurativa was 6,851,308 in 7MM.
The Market drivers of Hidradenitis Suppurativa are
1. Growing Prevalent Patient Pool
2. Increasing awareness of the disease
3. Improvement in healthcare economy and affordable treatment options
The key players in Hidradenitis Suppurativa market include InflaRx, Novartis Pharmaceuticals, ChemoCentryx, AbbVie and others.
For more detailed information visit: https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market